At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
HM15912drug
Likely dose
HM15912 0.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HM15912(Sonefpeglutide) in Subjects With Renal Impairment and Matched Control Subjects With Normal Renal Function
In Brief
A Phase 1 clinical trial evaluating HM15912 for Renal Impairment. Completed, enrolled 16 participants across 4 sites.
Detailed Summary
An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HM15912 in Subjects with Renal Impairment and Matched Control Subjects with Normal Renal Function
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Impairment
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
Enrollment StartDec 2022
First PostedFeb 2023
Primary CompletionAug 2023
TodayJul 2026
First PostedFeb 3, 2023
Enrollment StartDec 2, 2022
Primary CompletionAug 15, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 3.4 years ago
Interventions
HM15912drug
Singe subcutaneous administration of HM15912 0.5 mg/kg